Cargando…
Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States
BACKGROUND: Before the official US Food and Drug Administration approval in 2021, pediatric hematologists across the United States have used direct oral anticoagulants (DOACs) “off-label” and based on extrapolation from labeling for adults with venous thromboembolism (VTE) and interim results of ped...
Autores principales: | Corrales-Medina, Fernando F., Raffini, Leslie, Recht, Michael, Santos, Jarren, Thornburg, Courtney D., Davila, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031368/ https://www.ncbi.nlm.nih.gov/pubmed/36970740 http://dx.doi.org/10.1016/j.rpth.2022.100001 |
Ejemplares similares
-
Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
por: Al-Ghafry, Maha, et al.
Publicado: (2022) -
Editorial: Pediatric Venous Thromboembolism
por: Branchford, Brian R., et al.
Publicado: (2018) -
Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016) -
Prevention of Hospital-Acquired Venous Thromboembolism in Children: A Review of Published Guidelines
por: Faustino, E. Vincent S., et al.
Publicado: (2017) -
Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the
Treatment of Challenging Patient Populations
por: Moyer, Genevieve Claire, et al.
Publicado: (2018)